Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DATHAN HAMANN

Allopathic & Osteopathic Physicians Dermatology

NPI
1760801070
CMS profile
2784941
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$30,300.00

127 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DATHAN HAMANN

NPI 1760801070 · CMS profile ID 2784941

Allopathic & Osteopathic Physicians / Dermatology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760801070?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DATHAN HAMANN, NPI 1760801070, CMS profile ID 2784941. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760801070?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DATHAN HAMANN, NPI 1760801070, CMS profile ID 2784941. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760801070?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DATHAN HAMANN, NPI 1760801070, CMS profile ID 2784941, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1760801070?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

127 matching records · $30,300.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 127 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–127 of 127.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $35.8403/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226068160 CMS
Lilly USA, LLC $19.3603/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186622260 CMS
LEO Pharma Inc. $10.4502/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252009496 CMS
Organon LLC $23.5602/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237770814 CMS
Botanix SB Inc $21.0602/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246260082 CMS
GENZYME CORPORATION $9.7902/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233240449 CMS
PFIZER INC. $3,125.0002/27/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1229949733 CMS
Galderma Laboratories, L.P. $7.0702/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234650548 CMS
PFIZER INC. $5.1602/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229950512 CMS
Janssen Biotech, Inc. $21.8402/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174510034 CMS
ABBVIE INC. $18.2902/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201995465 CMS
Regeneron Healthcare Solutions, Inc. $36.1702/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212936858 CMS
PFIZER INC. $17.9802/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229946383 CMS
UCB, Inc. $10.3402/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224373734 CMS
LEO Pharma Inc. $7.2102/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252009494 CMS
PFIZER INC. $38.2302/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229942944 CMS
PFIZER INC. $147.0602/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1230240760 CMS
PFIZER INC. $819.5202/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1230240769 CMS
PFIZER INC. $186.5202/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231147908 CMS
ABBVIE INC. $30.4601/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201995463 CMS
KYOWA KIRIN, INC. $29.5801/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222086117 CMS
PFIZER INC. $6.7801/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229953765 CMS
Lilly USA, LLC $25.6401/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186635643 CMS
UCB, Inc. $28.9601/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224373732 CMS
LEO Pharma Inc. $8.2401/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252009492 CMS
Lilly USA, LLC $18.7201/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186599824 CMS
Regeneron Healthcare Solutions, Inc. $9.8101/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212936856 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $200.47 2
PY2020 $77.76 5
PY2021 $424.58 14
PY2022 $1,097.97 46
PY2023 $4,719.41 64
PY2024 $19,293.77 90
PY2025 $30,300.00 127

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $164,513.89 81
PY2024 Recipient $26.66 1
PY2024 Principal investigator $68,226.66 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

81 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 12/19/2025 Non-covered Recipient Entity
Probity Medical Research Corp
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226094210
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,271.84 12/03/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289182
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Saguaro Dermatology
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235994119
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,649.08 10/22/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223287249
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,573.80 10/17/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287131
Principal investigator 1 SANOFI US SERVICES INC. $1,050.00 10/03/2025 Non-covered Recipient Entity
Probity Medical Research Corp
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226094197
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,017.67 09/24/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285870
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,628.80 09/10/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223285277
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,054.91 08/22/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284563
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,656.17 08/20/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284443
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,220.82 08/13/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223284183
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 07/23/2025 Non-covered Recipient Entity
Probity Medical Research Corp
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226094152
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,628.80 07/23/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223283052
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,628.80 06/20/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223281712
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,834.37 06/13/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223281240
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,628.80 05/14/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223279782
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,830.95 05/07/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223279126
Principal investigator 1 Incyte Corporation $1.96 05/02/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583910
Principal investigator 1 Incyte Corporation $33.96 05/02/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583913
Principal investigator 1 Incyte Corporation $58.78 05/02/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583917
Principal investigator 1 Incyte Corporation $32.36 05/02/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583921
Principal investigator 1 Incyte Corporation $58.78 05/02/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583925
Principal investigator 1 Incyte Corporation $148.85 05/02/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583928
Principal investigator 1 Incyte Corporation $32.36 05/02/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583931
Principal investigator 1 Incyte Corporation $6.76 05/02/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583935
Principal investigator 1 Incyte Corporation $1.96 05/02/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583939
Principal investigator 1 Incyte Corporation $120.06 05/02/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583943
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25,177.84 05/02/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278900
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 04/16/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223278168
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,814.40 04/11/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223277964
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,634.55 04/11/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277970
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,746.63 03/14/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223276729
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,410.50 03/05/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223276035
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $509.10 02/26/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223275675
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,555.00 02/26/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275677
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,400.00 02/19/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223275397
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,919.08 02/12/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223275199
Principal investigator 1 Incyte Corporation $33.96 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583737
Principal investigator 1 Incyte Corporation $3.43 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583741
Principal investigator 1 Incyte Corporation $27.75 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583745
Principal investigator 1 Incyte Corporation $13.60 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583748
Principal investigator 1 Incyte Corporation $12.20 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583752
Principal investigator 1 Incyte Corporation $190.62 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583757
Principal investigator 1 Incyte Corporation $9.45 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583762
Principal investigator 1 Incyte Corporation $9.72 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583767
Principal investigator 1 Incyte Corporation $114.50 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583771
Principal investigator 1 Incyte Corporation $9.90 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583775
Principal investigator 1 Incyte Corporation $1.40 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583780
Principal investigator 1 Incyte Corporation $6.25 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583783
Principal investigator 1 Incyte Corporation $6.88 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583787
Principal investigator 1 Incyte Corporation $103.25 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583791
Principal investigator 1 Incyte Corporation $6.76 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583797
Principal investigator 1 Incyte Corporation $6.76 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583802
Principal investigator 1 Incyte Corporation $0.44 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583805
Principal investigator 1 Incyte Corporation $119.08 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583809
Principal investigator 1 Incyte Corporation $119.08 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583815
Principal investigator 1 Incyte Corporation $3.32 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583819
Principal investigator 1 Incyte Corporation $104.56 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583823
Principal investigator 1 Incyte Corporation $1.02 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583827
Principal investigator 1 Incyte Corporation $2.04 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583833
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583836
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583839
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583843
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583847
Principal investigator 1 Incyte Corporation $1.47 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583851
Principal investigator 1 Incyte Corporation $0.22 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583855
Principal investigator 1 Incyte Corporation $120.06 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583858
Principal investigator 1 Incyte Corporation $76.92 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583862
Principal investigator 1 Incyte Corporation $43.32 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583867
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583872
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583875
Principal investigator 1 Incyte Corporation $2.94 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583880
Principal investigator 1 Incyte Corporation $54.62 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583884
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583888
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583892
Principal investigator 1 Incyte Corporation $29.52 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583897
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583901
Principal investigator 1 Incyte Corporation $24.36 02/06/2025 Non-covered Recipient Entity
SAGUARO DERMATOLOGY
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240583906
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 01/24/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274477
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,249.16 01/17/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223274233
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 01/15/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223273935

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $0.00 1
PY2025 Value of interest $1,338,598.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

1 record · PY2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 Allerderm Laboratories $0.00 $1,338,598.00 The current investment value equals net tangible book value. Physician Covered Recipient No dispute reported 06/30/2026 1254961083